最近，新型生物制剂或小分子药物已被引入，以克服与抗肿瘤坏死因子α药物治疗炎症性肠病（IBD）相关的未满足的需求。在这些新药中，抗整合素药物通过阻断整合素和细胞粘附分子之间的相互作用来阻止白细胞向肠道的运输。维多珠单抗（抗α4β7）是被批准用于治疗溃疡性结肠炎和克罗恩病的最广泛使用的抗整合素药物。它已被证明在诱导和维持治疗中均有效，并且由于肠道选择性而具有良好的安全性。已经开发出几种结合临床、遗传、免疫和肠道微生物标志物的模型来预测 IBD 对维多珠单抗的反应。 Etrolizumab（抗 β7）通过 α4β7 阻断白细胞运输，并通过 αEβ7 整合素阻断细胞粘附。此外，皮下注射维多珠单抗的引入显示出相似的疗效和安全性，并提高了患者的便利性。其他研究性抗整合素疗法包括 abrilumab（抗 α4β7 IgG2）、PN-943（口服和肠道限制性 α4β7 拮抗肽）、AJM300（口服活性 α4 小分子抑制剂）和 ontamalimab（抗 MAdCAM-1 IgG） ）。

Recently, novel biologics or small molecular drugs have been introduced for overcoming the unmet needs associated with anti-tumor necrosis factor α agents for inflammtory bowel disease (IBD) treatment. Among these novel drugs, anti integrin agents block leukocyte trafficking to the intestine by blocking the interaction between integrin and cell adhesion molecules. Vedolizumab (anti-α4β7) is most widely used anti-integrin approved in both ulcerative colitis and Crohn's disease .It has been shown to be effective in both induction and maintenance therapy with a favorable safety profile due to gut selectivity. Several models incorporating clinical, genetic, immune and gut microbial markers to predict response to vedolizumab in IBD have been developed. Etrolizumab (anti-β7) blocks leukocyte trafficking via α4β7 and cell adhesion via αEβ7 integrins. In addition, the introduction of subcutaneous vedolizumab showed similar efficacy and safety with improved patients' convenience. Other investigational anti-integrin therapies include abrilumab (anti-α4β7 IgG2), PN-943 (orally administered and gut-restricted α4β7 antagonist peptide), AJM300 (orally active small molecule inhibitor of α4), and ontamalimab (anti-MAdCAM-1 IgG).